Skip to main content
NCBI home page
Public Health Reports logoLink to Public Health Reports
. 1995 Nov-Dec;110(6):720–725.

Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries?

R Snow 1, J D Babish 1, A M McBean 1
PMCID: PMC1381815  PMID: 8570826

Abstract

To learn whether the risk of revaccination in adults should limit its use, the authors investigated whether adverse events requiring hospitalization occurred in a group of Medicare enrollees revaccinated with pneumococcal polysaccharide vaccine. A prospective cohort analysis and case study of revaccinated people involved five percent of all elderly Medicare enrollees from 1985 through 1988, consisting of 66,256 people receiving one dose of vaccine and 1,099 receiving two doses. Comparison was made of the hospitalization rate within 30 days after revaccination and rates of singly vaccinated persons using discharge diagnosis for all those hospitalized during the 30 days after revaccination. No significant difference was found between the hospitalization rate of the revaccinated cohort and comparison group. No adverse reactions attributable to pneumococcal polysaccharide vaccine causing hospitalization were identified among 39 revaccinated persons who were hospitalized within 30 days of revaccination. Revaccination of elderly Medicare beneficiaries does not cause events serious enough to require hospitalization. Vaccination of persons according to the Public Health Service Immunization Practice Advisory Committee guidelines is recommended when the prior immunization status is unknown.

Full text

PDF
720

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolan G., Broome C. V., Facklam R. R., Plikaytis B. D., Fraser D. W., Schlech W. F., 3rd Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med. 1986 Jan;104(1):1–6. doi: 10.7326/0003-4819-104-1-1. [DOI] [PubMed] [Google Scholar]
  2. Fedson D., Henrichsen J., Mäkelä P. H., Austrian R. Immunization of elderly people with polyvalent pneumococcal vaccine. Infection. 1989 Nov-Dec;17(6):437–441. doi: 10.1007/BF01645568. [DOI] [PubMed] [Google Scholar]
  3. Hilleman M. R., Carlson A. J., Jr, McLean A. A., Vella P. P., Weibel R. E., Woodhour A. F. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis. 1981 Mar-Apr;3 (Suppl):S31–S42. doi: 10.1093/clinids/3.supplement_1.s31. [DOI] [PubMed] [Google Scholar]
  4. McBean A. M., Babish J. D., Prihoda R. The utilization of pneumococcal polysaccharide vaccine among elderly Medicare beneficiaries, 1985 through 1988. Arch Intern Med. 1991 Oct;151(10):2009–2016. [PubMed] [Google Scholar]
  5. Nelson K., Goldman J. A., Perlino C. A. Severe local reactions to pneumococcal vaccine. South Med J. 1980 Feb;73(2):264–265. doi: 10.1097/00007611-198002000-00042. [DOI] [PubMed] [Google Scholar]
  6. Shapiro E. D., Berg A. T., Austrian R., Schroeder D., Parcells V., Margolis A., Adair R. K., Clemens J. D. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991 Nov 21;325(21):1453–1460. doi: 10.1056/NEJM199111213252101. [DOI] [PubMed] [Google Scholar]
  7. Shapiro E. D., Clemens J. D. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med. 1984 Sep;101(3):325–330. doi: 10.7326/0003-4819-101-3-325. [DOI] [PubMed] [Google Scholar]
  8. Sims R. V., Steinmann W. C., McConville J. H., King L. R., Zwick W. C., Schwartz J. S. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med. 1988 May;108(5):653–657. doi: 10.7326/0003-4819-108-5-653. [DOI] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES